StockData
Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc. (GLSI) stock

GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 6/30
$20.58+1.88 (+10.05%)

Close on Nov 18, 2026Market cap $302.08MP/E –Yield –

Greenwich LifeSciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Greenwich LifeSciences's operating income for the twelve months ending Jun 30, 2026 was -$21.87M. For fiscal 2025 it was -$19.45M. The highest annual figure on record is -$1.86M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.45M–
FY2024Dec 31, 2024-$17.64M–
FY2023Dec 31, 2023-$9.33M–
FY2022Dec 31, 2022-$8.04M–
FY2021Dec 31, 2021-$4.60M–
FY2020Dec 31, 2020-$1.86M–
FY2019Dec 31, 2019-$3.43M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.02M–
Q1 FY2026Mar 31, 2026-$5.73M–
Q4 FY2025Dec 31, 2025-$7.94M–
Q3 FY2025Sep 30, 2025-$4.17M–
Q2 FY2025Jun 30, 2025-$3.77M–
Q1 FY2025Mar 31, 2025-$2.77M–
Q4 FY2024Dec 31, 2024-$9.71M–
Q3 FY2024Sep 30, 2024-$2.73M–
Q2 FY2024Jun 30, 2024-$2.66M–
Q1 FY2024Mar 31, 2024-$2.54M–
Q4 FY2023Dec 31, 2023-$2.84M–
Q3 FY2023Sep 30, 2023-$2.50M–
Q2 FY2023Jun 30, 2023-$1.75M–
Q1 FY2023Mar 31, 2023-$2.24M–
Q4 FY2022Dec 31, 2022-$2.89M–
Q3 FY2022Sep 30, 2022-$2.38M–
Q2 FY2022Jun 30, 2022-$773.31K–
Q1 FY2022Mar 31, 2022-$1.99M–
Q4 FY2021Dec 31, 2021-$2.38M–
Q3 FY2021Sep 30, 2021-$866.69K–
Q2 FY2021Jun 30, 2021-$753.45K–
Q1 FY2021Mar 31, 2021-$600.61K–
Q4 FY2020Dec 31, 2020-$1.15M–
Q3 FY2020Sep 30, 2020-$256.87K–
Q2 FY2020Jun 30, 2020-$210.43K–
Q1 FY2020Mar 31, 2020-$244.64K–
Q4 FY2019Dec 31, 2019-$336.54K–
Q3 FY2019Sep 30, 2019-$336.01K–

More Greenwich LifeSciences figures

See a number that looks wrong?